Clinical Trial Update: Study Evaluating the Efficacy and Safety of Obeticholic Acid in Subjects With Compensated Cirrhosis Due to Nonalcoholic Steatohepatitis [Phase 3]

View source ↗

Summary

Phase 3 study evaluating obeticholic acid for compensated cirrhosis due to nonalcoholic steatohepatitis has completed with results posted in 2023.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Compensated Cirrhosis
• Nonalcoholic Steatohepatitis

Drugs mentioned

• Obeticholic acid (obeticholic acid)

Snippet

Sponsor: Intercept Pharmaceuticals | Conditions: Compensated Cirrhosis, Nonalcoholic Steatohepatitis | Phase 3 | Status: COMPLETED | Results posted: 2023-10-23